|
Cytokine
|
Group No.
|
Group name
|
% Positive cells in tumors
(X ± SD)
|
Score
(X ± SD)
|
|---|
|
TNFα
|
I
|
DCIS
|
67.3 ± 24.7
|
134.8 ± 82.4
|
| |
II
|
IDC-no-relapse
|
65.9 ± 23.7
|
141.9 ± 81.1
|
| |
III
|
IDC-with-relapse
|
85.0 ± 6.8
|
191.0 ± 70.3
|
| | |
p value
|
0.0008
|
0.0331
|
|
IL-1β
|
I
|
DCIS
|
69.3 ± 21.6
|
117.6 ± 80.1
|
| |
II
|
IDC-no-relapse
|
55.7 ± 29.3
|
121.2 ± 96.5
|
| |
III
|
IDC-with-relapse
|
84.8 ± 11.5
|
206.2 ± 76.2
|
| | |
p value
|
<0.0001
|
0.0004
|
- The table provides information on the prevalence of TNFα and IL-1β expression in tumors of breast cancer patients, with analyses that were performed only on patients whose tumors expressed the cytokines: DCIS group = Group I: TNFα n = 15, IL-1β n = 18; IDC-no-relapse group = Group II: TNFα n = 17, IL-1β n = 15; IDC-with-relapse group = Group III: TNFα n = 29, IL-1β n = 31. Each of the TNFα- and IL-1β-positive tumors were analyzed for % positive cells in the tumors, intensity of expression of the cytokines, and score (as described in "Methods"). The table provides the X ± SD of % cells positive for TNFα and IL-1β, and the X ± SD of the expression scores of TNFα and IL-1β in the three groups of patients.
- For each cytokine, group means were compared by one-way analysis of variance. Whenever a significant effect of group was observed, pair-wise comparisons between groups were performed. The results of the statistical analyses have shown that: (1) For % TNFα-positive cells, p = 0.0008: Group III was statistically different from Groups I and II. (2) For TNFα score, p = 0.0331: Paired comparisons did not identify specific significant differences between the groups of patients. (3) For % IL-1β positive cells, p < 0.0001: All three groups were statistically different from each other. (4) For IL-1β score, p = 0.0004: Group III was statistically different from Groups I and II.
